Target intelligence / Profile preview

DNA topoisomerase 4 subunit B (ParE) (ParE)

Target
ParE
Molecular classification
Enzyme, Type II topoisomerase, ATP-dependent DNA topoisomerase
01

Overview

DNA topoisomerase IV is an essential bacterial enzyme that plays a critical role in managing DNA supercoiling and unlinking intertwined daughter chromosomes (decatenation) during DNA replication (UniProt P0A7G6; PMID: 9293187). It is a heterotetrameric Type II topoisomerase consisting of two ParC subunits and two ParE subunits. The ParE subunit (also known as subunit B) contains the ATP-binding domain and provides the energy required for the enzyme's catalytic cycle through ATP hydrolysis (UniProt P0A7G6; PMID: 24597508). This enzyme is a primary target for the fluoroquinolone class of antibiotics, which interfere with the DNA ligation step, resulting in the accumulation of double-strand DNA breaks and subsequent bacterial cell death (PMID: 9371354; PMID: 24597508). Resistance to these antibiotics frequently arises through specific mutations in the ParE or ParC subunits that reduce drug binding affinity (PMID: 24597508). Topoisomerase IV is distinct from DNA gyrase, although both are Type II topoisomerases and share structural and functional similarities (PMID: 9293187).

Other names
DNA topoisomerase IV subunit BParEGrlBDNA topoisomerase IV subunit EATP-dependent DNA topoisomerase IV subunit B
02

Mechanism of action

Fluoroquinolones stabilize the covalent enzyme-DNA cleavage complex, preventing DNA religation and causing double-strand breaks (PMID: 9293187, 24597508). Aminocoumarins inhibit the ATPase activity of the ParE subunit by competing with ATP binding (PMID: 9293187).

03

Biological functions

DNA decatenationDNA relaxationChromosome segregationATP hydrolysis
04

Disease associations

Infection
05

Safety considerations

Development of antimicrobial resistanceFluoroquinolone-associated disability (FQAD)Tendonitis and tendon ruptureQT interval prolongationCentral nervous system toxicity
06

Interacting drugs

Ciprofloxacin

5 more in the full profile.

07

Biomarkers

parE gene mutationsQuinolone resistance-determining region (QRDR) mutationsMinimum inhibitory concentration (MIC)

Beyond the preview

Go deeper on DNA topoisomerase 4 subunit B (ParE) (ParE).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNA topoisomerase 4 subunit B (ParE) (ParE).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call